The first subject has been dosed in a Phase I biomarker study of apimostinel, a rapid-acting N-methyl-D-aspartate receptor (NMDAR) modulator for major depressive disorders (MDD). The injectable treatment was developed by clinical-stage biotechnology company Gate Neurosciences for acute depressive disorders such as postpartum and episodic depression, and depression with suicidality. Apimostinel previously demonstrated proof-of-concept in […]